Genprex Administers First Dose In Acclaim-3 Clinical Study Of Reqorsa Immunogene Therapy Combined With Tecentriq To Treat Small Cell Lung Cancer
$GNPX
Biotechnology: Pharmaceutical Preparations
Health Care
- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).